MedTrace Logo

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06595238 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 262

Last updated 2025-12-17

No results posted yet for this study

Summary

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity

Conditions

  • Obesity or Overweight

Interventions

DRUG

AZD6234

IMP injected subcutaneously, once a week. Unit dose strength as per CSP

DRUG

Placebo comparator

Placebo matching IMP dose injected subcutaneously, once a week.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2025-08-08
Completion
2025-12-03
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Japan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06595238 on ClinicalTrials.gov